The UK Government has recently decided to maintain funding for clinical research based within the NHS for the next 5 years at its current level of approximately £1 billion per year. The main aims of this funding are to ensure that NHS patients are provided with the best evidence-based care; that existing and new treatments are worthwhile, balancing cost and benefit; and to demonstrate that the UK healthcare sector is 'open for business', emphasising economic return from UK-based innovations and attraction of investment from abroad. Subsequent spending reviews will look closely at whether these aims are being achieved. A sizeable component of this money is spent by the National Institute for Health Research (NIHR) on supportive infrastructure backed by financial incentives to help NHS organisations contribute effectively to the national research effort. This is based on NIHR research networks that are currently undergoing rationalisation.
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For urological patients and clinicians this funding has meant a dramatic upsurge in the number of multi-centre studies being set up and a consequent need to make sure awareness and participation is maximised. The studies cover the complete range of research design, from biomarker and early stage drug studies to large pragmatic trials comparing new and established treatments. Although research on urological cancers continues to be a major focus, studies addressing research questions in stone disease, reconstructive urology, urogynaecology, andrology and lower urinary tract dysfunction are now opening.
How can urologists contribute? Well, there are many ways but perhaps the most important is to have knowledge of what trials are recruiting in a particular area and ask the question at each patient encounter: 'is there a research study that this patient can be offered'. This is now standard at cancer multidisciplinary team meetings but needs to be spread to all other areas of practice as well. To facilitate this, national studies need urologists to put themselves forward as local principal investigators (PI) to enable gaining of permission to open the study within a NHS organisation. This is usually not too onerous a role, but does commit the PI to recruiting at least one participant. It is important that colleagues working in a department help each other to achieve effective recruitment and work together to access support from the local Trust Research and Development (R & D) team.
A part of this research awareness-raising, the Editorial Board at the JCU has initiated a regular feature to publicise currently recruiting trials and to inform the UK urology community how to make best use of the current NHS research funding opportunities. This issue looks at a urological cancer trial (POUT) and a reconstructive urology trial (OPEN); both are looking for new sites and to increase recruitment and so will be delighted to hear of your interest. I will be very happy to discuss any ideas you may have for future issues or respond to any other comments. 
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